Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
By Parameswaran Nair, M. Pizzichini, M. Kjarsgaard, M. Inman, A. Efthimiadis, E. Pizzichini, F. Hargreave, P. O'Byrne. New England Journal of Medicine, 2009
1,281 citations recorded by the source corpus.
Subfields: Physiology, Rheumatology, Sociology and Political Science
View Paper: https://www.semanticscholar.org/paper/1630e5f4689439082ccc2f9137f6c9acdc01e5dd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Physiology
In Rheumatology
In Sociology and Political Science
Citations in the corpus
- Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease (2018, positive): “The suppression of peripheral eosinophilia by anti-IL-5 therapy does not always correlate with clinical response or normalization of sputum eosinophilia [51].”
- Eosinophils: changing perspectives in health and disease (2012, background): “Humanized IL-5-specific monoclonal antibodies (namely, mepolizumab and reslizumab) and a humanized IL-5Rα-specific monoclonal antibody (namely, benralizumab) are under exploration for the therapeutic management of dysregulated eosinophilia [92] [93] [94] [95] [96] 125 .”
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma (2013, background): “Eosinophilic inflammation, for instance, is likely to have a Th2 immune component, a reflection of adaptive immunity, as evidenced by four separate studies demonstrating efficacy of a monoclonal antibody to IL-5 in eosinophilic severe asthma in adults [13, 67-69].”